KROSNEUTRAL

Gross Margin

-9.8%

Higher than 5% of Healthcare sector peers

Updated 1030h ago

Sector Performance

5th percentile

KROS

-9.8%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Keros Therapeutics, Inc. (KROS) has a Gross Margin of -9.8% as of May 2026.

This places KROS in the 5th percentile of the Healthcare sector, which has a median Gross Margin of 68.9% and a sector average of -20.2%. KROS's Gross Margin is 114.2% below the sector median, a significant divergence that warrants closer examination. In context: Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

Frequently Asked Questions

What does the Gross Margin tell investors about KROS?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does KROS's Gross Margin compare to its sector?

KROS's Gross Margin of -9.8% compares to a Healthcare sector median of 68.9%, placing it in the 5th percentile.

Who are KROS's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: BLUE (68.4%), AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.